![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Preclinical research recently completed by Immunic and collaborators has shown that certain DHODH inhibitors, including it's lead asset, IMU-838, strongly synergize with selected nucleoside analogues to inhibit SARS-CoV-2 replication in vitro.
Lead Product(s): Vidofludimus calcium anhydrous,Beta-D-N4-hydroxycytidine
Therapeutic Area: Infections and Infectious Diseases Product Name: IMU-838
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: University Medical Center Goettingen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 22, 2021